Pasqua Wines invests in Charles Smith wine brand alongside distribution deal
In a statement, Pasqua Wines said it will distribute House of Smith's K Vintners, Real Wine and Sex wine brands across global markets from September.
Pasqua is to take up to a 20% stake in the Real Wine brand, tied to "performance and growth targets", a joint statement said.
Charles Smith, founder of the US wine group of the same name, said the partnership gives his company 'access to an international network that will allow us to share the story of our wines, rooted in place, purpose, and passion, with more people than ever before'.
Details of the prospective markets where Pasqua will manage distribution for Charles Smith's three wine brands are not being disclosed for now. The US market however will not be included in the agreement, with Charles Smith already having distribution here, Pasqua Wines CEO Riccardo Pasqua told Just Drinks.
Pasqua sells its wines, which include the 11 Minutes and Hey French labels, to over 70 countries worldwide, including Scandinavia, Dubai, Australia and South America.
Riccardo added: "Although Charles Smith's wines have been available in various markets, their international reach has not been as extensive or fully developed as the network Pasqua can provide."
In its most recent results, Pasqua reported a consolidated turnover of €63.5m ($74.36m), growing 6% year-on-year. This was fuelled by performance in the US which makes up a third of the company's exports.
Reflecting on the Real Wine stake, Pasqua said both wine businesses had formed a 'deeper alliance, not just a commercial partnership,' he said.
He added: 'To underscore their long-term commitment, Pasqua becomes a minority partner in Real Wine, reflecting their intent to go beyond distribution into genuine partnership based on shared growth."
When asked about its distribution strategy for the Charles Smith wines, Pasqua said the winery is looking to develop a 'tailor-made strategy for each market' and is 'evaluating both the on‑trade and off‑trade channels according to the segment of Charles Smith's portfolio selected for that specific territory".
Charles Smith used to own a clutch of wine brands under the Charles Smith Wines title. These were sold to Constellation Brands in 2016, and eventually sold to The Wine Group in 2022.
Ackley Brands acquired the business last year. The deal included the brands Band of Roses, Kung Fu Girl, Eve, Chateau Smith, The Velvet Devil and Boom Boom.
Charles Smith renamed his wine company House of Smith in 2021.
"Pasqua Wines invests in Charles Smith wine brand alongside distribution deal " was originally created and published by Just Drinks, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Bloomberg
9 minutes ago
- Bloomberg
Trump Reaches Japan Deal With Tariff Rate Set at 15%
Good morning. Donald Trump announces a trade deal with Japan. The German and French leaders meet in Berlin tonight. And Ozzy Osbourne has died. Listen to the day's top stories. The US president announced a deal with Japan that sets tariffs on the nation's imports at 15%, including for autos—by far the biggest component of the trade deficit between the countries. The agreement provides some clarity on the broad contours of a new trade landscape. Talks continue with major economies including the European Union and India.


Bloomberg
9 minutes ago
- Bloomberg
China's Long Bonds Join Global Drop as US Trade Tensions Ease
A global selloff in longer-dated bonds has finally spilled over into Chinese debt, as easing US trade tensions and Beijing's efforts to tackle deflation damp demand for the notes. Futures on China's 30-year government securities fell as much as 0.7% on Wednesday to head for the longest run of losses since the contracts were launched in April 2023. Yields on similar-maturity debt in the cash market were on track to rise for a sixth straight session after climbing one basis point to 1.92%.
Yahoo
15 minutes ago
- Yahoo
AstraZeneca to invest $50B in US economy by 2030
British biopharmaceutical giant AstraZeneca plans to invest $50 billion in the U.S. by 2030, the company announced on Monday. The investment is expected to create tens of thousands of new, highly skilled direct and indirect jobs across the U.S., AstraZeneca said. The "cornerstone" of the investment is a proposed new multibillion-dollar manufacturing facility in Virginia that will produce drug substances for the company's weight management portfolio that includes oral GLP-1 medications. AstraZeneca said the facility will be its largest single manufacturing investment in the world. "Today's announcement underpins our belief in America's innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally," AstraZeneca CEO Pascal Soriot said in a statement. "I look forward to partnering with Governor Youngkin and his team to work on our largest single manufacturing investment ever. It reflects the Commonwealth of Virginia's desire to create highly-skilled jobs in science and technology, and will strengthen the country's domestic supply chain for medicines." Eli Lilly Investing $27B More In Us Manufacturing The investment also includes: expansion of its R&D facility in Gaithersburg, Maryland; R&D center in Kendall Square, Cambridge, Massachusetts; next-generation manufacturing facilities for cell therapy in Rockville, Maryland and Tarzana, California; continuous manufacturing expansion in Mount Vernon, Indiana; specialty manufacturing expansion in Coppell, Texas; new sites to supply clinical trials; and growing research and development investment in novel medicines. "We are proud that AstraZeneca has made the decision to bring substantial pharmaceutical production to our shores," Commerce Secretary Howard Lutnick said in a statement. "This historic investment is bringing tens of thousands of jobs to the U.S. and will ensure medicine sold in our country is produced right here." Read On The Fox Business App AstraZeneca also announced last November $3.5 billion of capital investment in the country, focused on R&D and manufacturing. The company said it included $2 billion of new investment that would create more than 1,000 new, high-skilled jobs in the U.S. Who's Investing In America? 23 Big Companies That Just Promised Billions Under Trump Part of the investment included a $300 million cell therapy manufacturing plant located in Maryland that opened in May. Once in operation, the site will use a relatively new cancer treatment called CAR-T cell therapy to help treat blood cancers like lymphoma and leukemia. The U.S. is AstraZeneca's largest market and represents 42% of the company's total revenue. The pharma giant's goal is to increase that figure to 50% by 2030. AstraZeneca employs 18,000 people and supports 92,000 jobs overall in the U.S. It also currently has 19 R&D, manufacturing and commercial sites in the country. The company said it contributed $5 billion directly to the nation's economy and created about $20 billion worth of overall value for the U.S. economy. Monday's announcement marks the latest investment in America under the Trump administration. Other drugmakers, including Bristol Myers Squibb, Roche, Eli Lilly and Johnson & Johnson, previously announced intentions to invest billions in the U.S. for R&D, manufacturing and factory article source: AstraZeneca to invest $50B in US economy by 2030